Micropenam Injection (Meropenem)

• Composition :
  Each vial contains: Meropenem 125 mg/ 500 mg/1 g Injection
• Indications :
  For treatment of pneumonia, nosocomial pneumonia, UTI, intra-abdominal infection, gynaecological infection, skin & soft tissue infection, meningitis, septicaemia & empiric treatment of presumed infection in adult patients with febrile neutropenia. In children, of the following infections caused by single or multiple bacteriasensitive to Meropenem: Pneumonias and Nosocomial Pneumonias, Uriniary Tract Infections, Gynaecological infections.
• Pharmacodynamics :
  Meropenem is a broad-spectrum carbapenem antibiotic. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa and PBPs 1, 2, and 4 of Staphylococcus aureus. Sulbactam is a synthetic beta-lactamase inhibitor. A feature that distinguishes sulbactam from other available beta-lactamase inhibitors is its direct antimicrobial activity against the Acinetobacter species and Bacteriodes fragilis.
• Dosage and administration :
  500 mg every 8 hours by intravenous infusion over 15 to 30 minutes for complicated skin and skin structure infections (cSSSI) for adult patients. When treating infections caused by Pseudomonas aeruginosa, a dose of 1 gram every 8 hours is recommended. 1 gram every 8 hours by intravenous infusion over 15 minutes to 30 minutes for intra-abdominal infections for adult patients. 1 gram every 8 hours by intravenous bolus injection (5 mL to 20 mL) over 3 minutes to 5 minutes for adult patients. Dosage should be reduced in adult patients with renal impairment
• Precautions and warnings :
  If an allergic reaction occurs, the drug should be discontinued and the appropriate therapy instituted. Seizures and other CNS experiences have been reported during treatment. Co-administration of Meropenem with valproic acid or divalproex sodium reduces the serum concentration of valproic acid potentially increasing the risk of breakthrough seizures. Clostridium difficle-asssociated diarrhoea has been reported. Patients with pre-existing liver disorders should have liver function monitored during treatment with meropenem.
• Use in pregnancy, lactation & pediatrics :
  Pregnancy Category B. has been reported to be excreted in human milk. Caution should be exercised when meropenem is administered to a nursing woman. The safety and effectiveness of meropenem have been established for paediatric patients 3 months of age and older with complicated skin and skin structure infections and bacterial meningitis, and for paediatric patients of all ages with complicated intra-abdominal infections.
• Drug interactions :
  The co-administration of probenecid with meropenem I.V. is not recommended. If administration of meropenem I.V. is necessary, then supplemental anti-convulsant therapy should be considered.
• Adverse reactions :
  Inflammation at the injection site, thrombophlebitis, injection site reaction, pain at the injection site, and oedema at the injection site. diarrhoea, nausea/vomiting, headache, rash, sepsis, constipation, apnoea, shock and pruritus.
• Therapy Area :
  Anti-Bacterials